Binding molecules binding PD-L1 and LAG-3

The present disclosure relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more s...

Full description

Saved in:
Bibliographic Details
Main Authors Wollerton Van Horck, Francisca, Kraman, Matthew, Hebeis, Barbara, Tuna, Mihriban, Gaspar, Miguel, Faroudi, Mustapha, Fosh, Natalie, Kmiecik, Katarzyna, Everett, Katy Louise, Campbell, Jamie, Sandy, Nikole
Format Patent
LanguageEnglish
Published 15.08.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the disclosure find application, for example, in cancer therapy.
Bibliography:Application Number: AU20170283181